{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:54:55Z","timestamp":1793663695434,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple Myeloma (MM) is a glutamine (Gln)-addicted cancer. Consequently, the MM bone microenvironment (BM) is characterized by lower Gln and higher glutamate (Glu) levels than those in pre-malignant monoclonal gammopathies. Such MM-dependent metabolic perturbation impairs osteoblast differentiation in the bone microenvironment, but its effect on osteoclast (OCL) bone resorption is still unknown. We first show that bone marrow mononuclear cells from MM patients release higher levels of Glu compared to those from patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). This increased Glu production correlates with elevated bone resorption activity. We then demonstrate that Glu stimulates OCL differentiation\n                    <jats:italic>via<\/jats:italic>\n                    the activation of NF-\u03baB-NFATc1 pathway in low-Glu BM samples from pre-malignant patients but not in high-Glu samples of MM patients. Secondly, the early phase of OCL formation was associated with high Glu intracellular content and induction of the Glu transporter EAAT1. Consistently, the pharmacological inhibition of EAAT1 hinders OCL differentiation by blocking the RANKL-dependent signaling pathway and actin cytoskeleton reorganization. Overall, our data indicate that high Glu levels in MM bone marrow are involved in OCL formation, suggesting that targeting Glu transport may represent a novel approach for the prevention of osteolytic lesions in MM patients.\n                  <\/jats:p>","DOI":"10.1038\/s41375-025-02715-2","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T06:25:45Z","timestamp":1753683945000},"page":"2492-2503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease"],"prefix":"10.1038","volume":"39","author":[{"given":"Denise","family":"Toscani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Lungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-1171","authenticated-orcid":false,"given":"Giuseppe","family":"Taurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano G.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Scita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Dalla Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas Thomas","family":"Iannozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Vescovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4211-7990","authenticated-orcid":false,"given":"Mattia","family":"Dessena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Sitzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-2939","authenticated-orcid":false,"given":"Ovidio","family":"Bussolati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-3774","authenticated-orcid":false,"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2715_CR1","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1038\/emm.2013.85","volume":"45","author":"M Jang","year":"2013","unstructured":"Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013;45:e45.","journal-title":"Exp Mol Med"},{"key":"2715_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.85","volume":"5","author":"C Ludwig","year":"2015","unstructured":"Ludwig C, Williams DS, Bartlett DB, Essex SJ, McNee G, Allwood JW, et al. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. Blood Cancer J. 2015;5:e359.","journal-title":"Blood Cancer J"},{"key":"2715_CR3","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-12-2917","volume":"19","author":"L Puchades-Carrasco","year":"2013","unstructured":"Puchades-Carrasco L, Lecumberri R, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Prosper F, et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res. 2013;19:4770\u20139.","journal-title":"Clin Cancer Res"},{"key":"2715_CR4","doi-asserted-by":"publisher","first-page":"e0202045","DOI":"10.1371\/journal.pone.0202045","volume":"13","author":"N Steiner","year":"2018","unstructured":"Steiner N, Muller U, Hajek R, Sevcikova S, Borjan B, Johrer K, et al. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. PloS one. 2018;13:e0202045.","journal-title":"PloS one"},{"key":"2715_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","volume":"128","author":"M Bolzoni","year":"2016","unstructured":"Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, et al. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood. 2016;128:667\u201379.","journal-title":"Blood"},{"key":"2715_CR6","doi-asserted-by":"crossref","unstructured":"Chiu M, Toscani D, Marchica V, Taurino G, Costa F, Bianchi MG, et al. Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability. Cancers. 2020;12:3267.","DOI":"10.3390\/cancers12113267"},{"key":"2715_CR7","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood. 2006;108:3992\u20136.","journal-title":"Blood"},{"key":"2715_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2009","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23:435\u201341.","journal-title":"Leukemia"},{"key":"2715_CR9","doi-asserted-by":"crossref","unstructured":"Gerov V, Gerova D, Micheva I, Nikolova M, Pasheva M, Nazifova N, et al. Circulating sRANKL, periostin, and osteopontin as biomarkers for the assessment of activated osteoclastogenesis in myeloma related bone disease. Cancers. 2023;15:5562.","DOI":"10.3390\/cancers15235562"},{"key":"2715_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.1984.tb09689.x","volume":"42","author":"F Fonnum","year":"1984","unstructured":"Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem. 1984;42:1\u201311.","journal-title":"J Neurochem"},{"key":"2715_CR11","doi-asserted-by":"crossref","unstructured":"Magi S, Piccirillo S, Amoroso S, Lariccia V. Excitatory amino acid transporters (EAATs): glutamate transport and beyond. Int J Mol Sci. 2019;20:5674.","DOI":"10.3390\/ijms20225674"},{"key":"2715_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0165-6147(00)01642-4","volume":"22","author":"TM Skerry","year":"2001","unstructured":"Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharm Sci. 2001;22:174\u201381.","journal-title":"Trends Pharm Sci"},{"key":"2715_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1254\/jphs.94.215","volume":"94","author":"E Hinoi","year":"2004","unstructured":"Hinoi E, Takarada T, Yoneda Y. Glutamate signaling system in bone. J Pharm Sci. 2004;94:215\u201320.","journal-title":"J Pharm Sci"},{"key":"2715_CR14","first-page":"423","volume":"2","author":"C Chenu","year":"2002","unstructured":"Chenu C. Glutamatergic regulation of bone resorption. J Musculoskelet Neuronal Interact. 2002;2:423\u201331.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2715_CR15","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1096\/fasebj.13.15.2179","volume":"13","author":"NM Peet","year":"1999","unstructured":"Peet NM, Grabowski PS, Laketic-Ljubojevic I, Skerry TM. The glutamate receptor antagonist MK801 modulates bone resorption in vitro by a mechanism predominantly involving osteoclast differentiation. FASEB J. 1999;13:2179\u201385.","journal-title":"FASEB J"},{"key":"2715_CR16","first-page":"128","volume":"4","author":"DJ Mason","year":"2004","unstructured":"Mason DJ. The role of glutamate transporters in bone cell signalling. J Musculoskelet Neuronal Interact. 2004;4:128\u201331.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2715_CR17","first-page":"166","volume":"8","author":"TM Skerry","year":"2008","unstructured":"Skerry TM. The role of glutamate in the regulation of bone mass and architecture. J Musculoskelet Neuronal Interact. 2008;8:166\u201373.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2715_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2008.04.060","volume":"589","author":"TH Lin","year":"2008","unstructured":"Lin TH, Yang RS, Tang CH, Wu MY, Fu WM. Regulation of the maturation of osteoblasts and osteoclastogenesis by glutamate. Eur J Pharm. 2008;589:37\u201344.","journal-title":"Eur J Pharm"},{"key":"2715_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S8756-3282(97)00295-0","volume":"22","author":"C Chenu","year":"1998","unstructured":"Chenu C, Serre CM, Raynal C, Burt-Pichat B, Delmas PD. Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone. 1998;22:295\u20139.","journal-title":"Bone"},{"key":"2715_CR20","first-page":"97","volume":"3","author":"KS Brakspear","year":"2012","unstructured":"Brakspear KS, Mason DJ. Glutamate signaling in bone. Front Endocrinol. 2012;3:97.","journal-title":"Front Endocrinol"},{"key":"2715_CR21","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1038\/s44319-024-00255-x","volume":"25","author":"G Hu","year":"2024","unstructured":"Hu G, Yu Y, Ren Y, Tower RJ, Zhang GF, Karner CM. Glutaminolysis provides nucleotides and amino acids to regulate osteoclast differentiation in mice. EMBO Rep. 2024;25:4515\u201341.","journal-title":"EMBO Rep"},{"key":"2715_CR22","doi-asserted-by":"crossref","unstructured":"Chiu M, Taurino G, Bianchi MG, Ottaviani L, Andreoli R, Ciociola T, et al. Oligodendroglioma cells lack glutamine synthetase and are auxotrophic for glutamine, but do not depend on glutamine anaplerosis for growth. Int J Mol Sci. 2018;19:1099.","DOI":"10.3390\/ijms19041099"},{"key":"2715_CR23","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1080\/10428194.2017.1421757","volume":"59","author":"S Vallet","year":"2018","unstructured":"Vallet S, Hoyle NR, Kyle RA, Podar K, Pecherstorfer M. A role for bone turnover markers beta-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leuk Lymphoma. 2018;59:2431\u20138.","journal-title":"Leuk Lymphoma"},{"key":"2715_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.11005\/jbm.2014.21.4.233","volume":"21","author":"JH Kim","year":"2014","unstructured":"Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 2014;21:233\u201341.","journal-title":"J Bone Metab"},{"key":"2715_CR25","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.4049\/jimmunol.164.10.5430","volume":"164","author":"AC Rimaniol","year":"2000","unstructured":"Rimaniol AC, Haik S, Martin M, Le Grand R, Boussin FD, Dereuddre-Bosquet N, et al. Na+-dependent high-affinity glutamate transport in macrophages. J Immunol. 2000;164:5430\u20138.","journal-title":"J Immunol"},{"key":"2715_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4161\/cam.27840","volume":"8","author":"D Georgess","year":"2014","unstructured":"Georgess D, Machuca-Gayet I, Blangy A, Jurdic P. Podosome organization drives osteoclast-mediated bone resorption. Cell Adh Migr. 2014;8:191\u2013204.","journal-title":"Cell Adh Migr"},{"key":"2715_CR27","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1124\/mol.65.4.1008","volume":"65","author":"K Shimamoto","year":"2004","unstructured":"Shimamoto K, Sakai R, Takaoka K, Yumoto N, Nakajima T, Amara SG, et al. Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters. Mol Pharm. 2004;65:1008\u201315.","journal-title":"Mol Pharm"},{"key":"2715_CR28","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1016\/S0021-9258(19)69127-1","volume":"256","author":"GC Gazzola","year":"1981","unstructured":"Gazzola GC, Dall\u2019Asta V, Bussolati O, Makowske M, Christensen HN. A stereoselective anomaly in dicarboxylic amino acid transport. J Biol Chem. 1981;256:6054\u20139.","journal-title":"J Biol Chem"},{"key":"2715_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67105-3","volume":"10","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, Broniowska K, Jessen E, Petterson XM, Bush AG, Gransee J, et al. Metabolomic and lipidomic profiling of bone marrow plasma differentiates patients with monoclonal gammopathy of undetermined significance from multiple myeloma. Sci Rep. 2020;10:10250.","journal-title":"Sci Rep"},{"key":"2715_CR30","first-page":"739","volume":"27","author":"T McNearney","year":"2000","unstructured":"McNearney T, Speegle D, Lawand N, Lisse J, Westlund KN. Excitatory amino acid profiles of synovial fluid from patients with arthritis. J Rheumatol. 2000;27:739\u201345.","journal-title":"J Rheumatol"},{"key":"2715_CR31","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.joms.2009.04.056","volume":"67","author":"AK Hajati","year":"2009","unstructured":"Hajati AK, Alstergren P, Nasstrom K, Bratt J, Kopp S. Endogenous glutamate in association with inflammatory and hormonal factors modulates bone tissue resorption of the temporomandibular joint in patients with early rheumatoid arthritis. J Oral Maxillofac Surg. 2009;67:1895\u2013903.","journal-title":"J Oral Maxillofac Surg"},{"key":"2715_CR32","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","volume":"87","author":"R Bataille","year":"1996","unstructured":"Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood. 1996;87:4762\u20139.","journal-title":"Blood"},{"key":"2715_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jcb.10625","volume":"90","author":"B Merle","year":"2003","unstructured":"Merle B, Itzstein C, Delmas PD, Chenu C. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J Cell Biochem. 2003;90:424\u201336.","journal-title":"J Cell Biochem"},{"key":"2715_CR34","first-page":"113","volume":"7","author":"N Kalariti","year":"2007","unstructured":"Kalariti N, Lembessis P, Papageorgiou E, Pissimissis N, Koutsilieris M. Regulation of the mGluR5, EAAT1 and GS expression by glucocorticoids in MG-63 osteoblast-like osteosarcoma cells. J Musculoskelet Neuronal Interact. 2007;7:113\u20138.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2715_CR35","doi-asserted-by":"publisher","first-page":"9077","DOI":"10.1073\/pnas.92.20.9077","volume":"92","author":"L Guerrini","year":"1995","unstructured":"Guerrini L, Blasi F, Denis-Donini S. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA. 1995;92:9077\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2715_CR36","doi-asserted-by":"publisher","first-page":"10193","DOI":"10.1523\/JNEUROSCI.19-23-10193.1999","volume":"19","author":"S Duan","year":"1999","unstructured":"Duan S, Anderson CM, Stein BA, Swanson RA. Glutamate induces rapid upregulation of astrocyte glutamate transport and cell-surface expression of GLAST. J Neurosci. 1999;19:10193\u2013200.","journal-title":"J Neurosci"},{"key":"2715_CR37","doi-asserted-by":"crossref","unstructured":"Blangy A, Bompard G, Guerit D, Marie P, Maurin J, Morel A, et al. The osteoclast cytoskeleton - current understanding and therapeutic perspectives for osteoporosis. J Cell Sci. 2020;133:jcs244798.","DOI":"10.1242\/jcs.244798"},{"key":"2715_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/jcp.24723","volume":"230","author":"J Takito","year":"2015","unstructured":"Takito J, Otsuka H, Yanagisawa N, Arai H, Shiga M, Inoue M, et al. Regulation of osteoclast multinucleation by the actin cytoskeleton signaling network. J Cell Physiol. 2015;230:395\u2013405.","journal-title":"J Cell Physiol"},{"key":"2715_CR39","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1046\/j.1471-4159.2003.02128.x","volume":"87","author":"SY Kim","year":"2003","unstructured":"Kim SY, Choi SY, Chao W, Volsky DJ. Transcriptional regulation of human excitatory amino acid transporter 1 (EAAT1): cloning of the EAAT1 promoter and characterization of its basal and inducible activity in human astrocytes. J Neurochem. 2003;87:1485\u201398.","journal-title":"J Neurochem"},{"key":"2715_CR40","doi-asserted-by":"publisher","first-page":"23725","DOI":"10.1074\/jbc.M115.649327","volume":"290","author":"P Karki","year":"2015","unstructured":"Karki P, Kim C, Smith K, Son DS, Aschner M, Lee E. Transcriptional Regulation of the Astrocytic Excitatory Amino Acid Transporter 1 (EAAT1) via NF-kappaB and Yin Yang 1 (YY1). J Biol Chem. 2015;290:23725\u201337.","journal-title":"J Biol Chem"},{"key":"2715_CR41","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1007\/s12035-017-0709-x","volume":"55","author":"P Karki","year":"2018","unstructured":"Karki P, Hong P, Johnson J Jr., Pajarillo E, Son DS, Aschner M, et al. Arundic acid increases expression and function of astrocytic glutamate transporter EAAT1 via the ERK, Akt, and NF-kappaB pathways. Mol Neurobiol. 2018;55:5031\u201346.","journal-title":"Mol Neurobiol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02715-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02715-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02715-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:12:21Z","timestamp":1758787941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02715-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2715"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02715-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}